Astrazeneca (AZN) Gains from Investment Securities (2014 - 2026)

Astrazeneca has reported Gains from Investment Securities for 12 years, with the latest figure at -$20.0 million in Q2 2026.

• On a quarterly basis, Gains from Investment Securities rose 35.48% year-over-year to -$20.0 million in Q2 2026; TTM through Jun 2026 was -$86.0 million, a 386.67% decrease from a year earlier, with the FY2025 full-year figure at -$97.0 million, down 131.19% from the prior year.
• Gains from Investment Securities was -$20.0 million for Q2 2026 at Astrazeneca, down from $1.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $293.0 million in Q4 2022, with the low at -$68.0 million in Q4 2025.
• Average Gains from Investment Securities over 5 years is $62.7 million, with a median of $1.0 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities soared 787.88% in 2022, then slumped 213.33% in 2025.
• Over 5 years, Gains from Investment Securities stood at $293.0 million in 2022, then plunged by 31.06% to $202.0 million in 2023, then sank by 70.3% to $60.0 million in 2024, then plunged by 213.33% to -$68.0 million in 2025, then jumped by 70.59% to -$20.0 million in 2026.
• The last three Gains from Investment Securities figures came in at -$20.0 million (Q2 2026), $1.0 million (Q1 2026), and -$68.0 million (Q4 2025), per Business Quant data.